ReviewCurrent clinical microbiology reports2021
A Review on the Effectivity of the Current COVID-19 Drugs and Vaccines: Are They Really Working Against the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants?
Review in Current clinical microbiology reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 2 syntheses or guidelines pooled it, 22 citations in OpenAlex.
- Characterization of the significant decline in humoral immune response six months post-SARS-CoV-2 mRNA vaccination: A systematic review.Journal of medical virology · 2022Pooled it
- A systematic review of Vaccine Breakthrough Infections by SARS-CoV-2 Delta Variant.International journal of biological sciences · 2022Pooled it
- Adaptation-proof SARS-CoV-2 vaccine design.Advanced functional materials · 2022Article
- Structural analysis of a simplified model reproducing SARS-CoV-2 S RBD/ACE2 binding site.Heliyon · 2022Article
- The Advantage of Using Immunoinformatic Tools on Vaccine Design and Development for Coronavirus.Vaccines · 2022Review
- Synthesis and In Silico Study of Some NewCurrent issues in molecular biology · 2022Article
- Potential COVID-19 Drug Candidates Based on Diazinyl-Thiazol-Imine Moieties: Synthesis and Greener Pastures Biological Study.Molecules (Basel, Switzerland) · 2022Article
- Probiotics for the Management of Infectious Diseases: Reviewing the State of the Art.Frontiers in microbiology · 2022Review
- A review on the induction of host immunity by the current COVID-19 vaccines and a brief non-pharmaceutical intervention to mitigate the pandemic.Bulletin of the National Research Centre · 2022Review
- mRNA Vaccines as an Efficient Approach for the Rapid and Robust Induction of Host Immunity Against SARS-CoV-2.SN comprehensive clinical medicine · 2022Review
- COVID-19 vaccines: their effectiveness against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its emerging variants.Bulletin of the National Research Centre · 2022Review
- How do the severe acute respiratory coronavirus 2 (SARS-CoV-2) and its variants escape the host protective immunity and mediate pathogenesis?Bulletin of the National Research Centre · 2022Review
- Nanomaterial-based drug delivery systems as promising carriers for patients with COVID-19.RSC advances · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewIn order to eradicate the COVID-19 pandemic, scientists around the world have been working very hard for a year or more with the motto of designing effective drugs and vaccines against the severe acute respiratory coronavirus 2 (SARS-CoV-2). Along with the positive results with the antiviral drugs and a few commercialized vaccines, the unresponsiveness as well as some side effects of such therapies have also been noticed, possibly due to the emergence of the SARS-CoV-2 variants. Therefore, current review summarized the actual effectiveness of the antivirals and vaccines which are in current use for the treatment of the COVID-19 patients. RECENT
findingsSo far, some drugs have been found with hopeful results among which remdesivir and arbidol are with momentous clinical progress. Besides drug designing, vaccine development has been a major effort whereby the mRNA-1273 (Moderna) and BNT162b2 (Pfizer-BioNTech) vaccines showed the required efficacy and have been approved by the US Food and Drug Administration (USFDA). SUMMARY: While a number of existing/repurposed/repositioned or new drugs and the currently used commercial vaccines against SARS-CoV-2 apparently seem to be effective against COVID-19 mitigation, the new variants of the virus as well as the recently increased cases raised the doubt about the usefulness of these agents. Current review figured out the efficacy of different drugs and vaccines in terms of their action potential against SARS-CoV-2 and further recommended some useful measures which may be useful for future remedies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.